Introduction
Graves’ disease (GD) is the most common cause of hyperthyroidism,
affecting 1.5% of the population. It is more prevalent in women than in
men (F/M 7:1)1. The most frequent extra-thyroidal
manifestation is Graves’ disease-associated orbitopathy (GO) affecting
more females than males with an annual incidence of 0.016% and 0.003%
respectively. This manifestation might lead to ocular adverse events as
a corneal breakdown or an optic neuropathy in 3 to 5% of such patients.
The European guidelines of Graves’ disease-associated orbitopathy was
commissioned by The European Thyroid Association to provide guidelines
for the management of GO. They recommend a high-dose intravenous
glucocorticoids (IV GC) be considered as a first-line treatment for
moderate-to-severe and active GO2.
Skeletal hemangiomas are rare benign tumors of blood vessels which occur
most commonly in the vertebral bodies followed by the skull. These
tumors account for 0.7% of bone neoplasma3.
We hereby report a case of a severe GO treated by IV GC who developed a
frontal bone hemangioma four months after the treatment.